Andere talen Voyager Therapeutics, Inc.

Aandelen

VYGR

US92915B1061

Geschatte realtime Cboe BZX Andere beurzen 16:19:30 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,51 ^USD	+1,21%		+0,67%	-10,55%

02/04	Voyager Therapeutics, Inc. Benoemt Robin Swartz tot hoofd boekhouding	CI
26/03	VOYAGER THERAPEUTICS, INC. : Guggenheim handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	22/04
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	16/04
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	16/04
Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer	02/04
Voyager Therapeutics, Inc. Announces CFO Changes	02/04
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	27/03
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	26/03
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) added to S&P Biotechnology Select Industry Index	18/03
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer	13/03
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer	13/03
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024	13/03
Voyager Therapeutics: Q4 Earnings Snapshot	28/02
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	28/02
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Voyager Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	27/02
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	26/02
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast	21/02
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research	20/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Voyager Therapeutics, Inc.

Aandelen

VYGR

US92915B1061

Andere talen

Filters